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Abstract
Background: A growing evidence base implicates vitamin D, sun exposure and latitude in the aetiology of multiple
sclerosis (MS), however there are less data on the associations of these variables with disease outcomes.
Methods: We undertook a cross-sectional survey of over 2000 people with MS recruited through internet platforms,
seeking self-reported data on geographical location, intentional sun exposure for health, and supplementation
with vitamin D, among other lifestyle variables. We also requested data on health-related quality of life (MSQOL-54),
self-reported doctor-diagnosed relapse rate, and disability (Patient Determined Disease Steps). Bivariate and multivariate
analyses were used for comparisons, including multiple linear regression modeling.
Results: Of 2301 participants, 82.3 % were female, median age was 45 years (IQR 38–53 years), with a median time since
diagnosis of 6 years (IQR 3-12 years), the majority (61.6 %) having relapsing-remitting MS. Nearly two-thirds (64.6 %) lived
in the Northern hemisphere, mostly in developed countries. Most (66.8 %) reported deliberate sun exposure to raise their
vitamin D level, and the vast majority (81.8 %) took vitamin D supplements, mostly 2000–5000 IU a day on
average. Unadjusted regression modeling incorporating deliberate sun exposure, latitude and vitamin D
supplementation showed strong associations of sun exposure with HRQOL which disappeared when controlling for
gender, age, disability, physical activity, and fish consumption. In contrast, associations between vitamin D
supplementation and HRQOL were maintained adjusting for these variables, with a dose–response effect. Only latitude
had significant adjusted associations with disability, with an increase of latitude by one degree (further from the
equator) predicting increased odds of moderate disability (OR 1.02 (95 % CI 1.01–1.04)) or high disability (OR 1.03 (95 %
CI 1.01–1.05)) compared to no/mild disability. Similarly, latitude was related to relapse rate, with increase in latitude of 1
degree associated with increased odds of having more relapses over the previous year (1.01 (1.00–1.02)).
Conclusions: We detected significant associations between latitude, deliberate sun exposure and vitamin D
supplementation and health outcomes of this large group of people with MS. Vitamin D is likely to have a key role in
these associations and its role in the health outcomes of people with MS urgently requires further study.
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Background
Multiple sclerosis (MS) is a progressive neurodegenerative
disease with a complex aetiology. MS is a familial disease,
and genetic background plays a significant role in disease
development, although of lesser importance than environ-
mental and lifestyle factors [1–3]. In contrast, for disease
progression or severity, no genetic markers have been
demonstrated to date [4]. This highlights the potentially
important role of risk factor modification as part of a
secondary preventive approach to disease management.
Previous research has examined potential environmental
and lifestyle risk factors for MS disease development and
progression. The longest studied of these factors has been
the association of increasing latitude with MS incidence
[5, 6]. A substantial body of research has linked this asso-
ciation to reduced sun exposure, probably largely through
low exposure to ultraviolet light mediated by reduced en-
dogenous vitamin D production [7]. Less attention has
been focused on the effects of sun exposure on MS disease
course, although clinical trials are now suggesting vitamin
D supplementation has a favourable effect. Some are sug-
gesting that vitamin D supplementation should now be
considered standard of care for people with MS (PwMS)
[8]. While opinion leaders in neurology have publicly
stated that if they themselves were diagnosed with early
demyelination, they would take high dose vitamin D sup-
plements, they still debate whether the evidence of benefit
is sufficiently strong to warrant routine supplementation
for their patients, and if so, at what dosage [9]. The effects
of sun exposure and vitamin D supplementation on MS
disease progression are biologically plausible, given their
known immunomodulatory effects in the context of the
central role of immune dysfunction in MS [10].
Through Web 2.0 platforms, we have assembled a large
cohort of PwMS from 57 countries for the purpose of
examining associations between environmental and life-
style factors and measures of quality of life and disease
outcomes. This cohort is somewhat unique in that it con-
tains a large proportion of PwMS actively modifying life-
style factors thought to be associated with MS disease
course, enabling robust comparisons between those who
do and do not modify such factors [11]. If sun exposure
and vitamin D supplementation have the beneficial effects
postulated in research to date, we would expect to see
associations in this cohort between the latitude of their
place of residence and these outcomes; we would also ex-
pect to see a signal of reduced relapse rate and disease
progression with vitamin D supplementation. This study
aimed to test these associations.
Methods
Participants and data collection
The methodology of this study has previously been de-
scribed in some detail [11]. Briefly, using the online
software SurveyMonkey®, we developed a webpage de-
scribing the study aims and inviting PwMS to take part.
We posted a link to this webpage on websites, blogs, for-
ums, and social media in which the principal investigator
(GJ) was actively involved, including his own website
(www.overcomingms.org; ‘OMS’). Online groups and
pages used by PwMS with over 500 members or followers
were targeted. Several follow up notices were posted over
the 15 week recruitment period. MS societies were also
asked to circulate details to their members.
After reading a participant information sheet, responders
were advised that participation in the survey would consti-
tute consent to the study. Inclusion criteria were adults of
18 years of age or more, who had been formally diagnosed
with MS by a medical doctor and who could undertake an
English language survey. We also sought contact details to
enable planned longitudinal follow up. Data were stored in
re-identifiable format, and access was restricted to mem-
bers of the research team. Ethical approval was granted by
St Vincent’s Hospital Melbourne Human Research Ethics
Committee (LRR 055/12).
Data collected and tools used
Overall, the survey consisted of 163 questions, and took
approximately 40 min to complete. Validated tools were
used where possible, although for several variables, tools
had not previously been validated. Socio-demographic
data included age, gender, current location of residence,
country of birth, cultural background, marital status,
number of children, employment, education, height and
weight. Disease-specific data included whether MS diag-
nosis had been confirmed by a medical doctor, year of
diagnosis, first year of symptoms, diagnostic investigations
undertaken, type of MS on diagnosis and currently. Partic-
ipants were asked with a researcher-devised question how
many physician-diagnosed relapses they had had in the
previous 12 months and the last 5 years. Level of disability
was assessed using the Patient-Determined Disease Steps
(PDDS), a validated self-reported surrogate tool to the Ex-
panded Disability Status Scale (EDSS) commonly used by
neurologists to assess gait disability [12]. PDDS is scored
ordinally from 0 (normal) to 8 (bed bound).
Health-related quality of life (HRQOL) was assessed
with the validated and widely used Multiple Sclerosis
Quality Of Life-54 (MSQOL-54), developed from the
RAND 36-Item Health Survey (SF-36) and supple-
mented with 18 additional items. MSQOL-54 consists of
52 items in 12 scales, and two single items, producing
two composite scores – the physical and mental health
composites [13]. Whether participants deliberately exposed
themselves to the sun to increase vitamin D production
(yes/no) and frequency and dosage of vitamin D supple-
mentation were recorded using researcher-developed ques-
tions, as there were no validated tools for these data.
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Vitamin D supplementation dose in International Units
(IU) (0, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000,
9000, 10,000, 20,000, 30,000, 40,000, 50,000, 100,000,
250,000, 500,000) and frequency (daily, every second day,
weekly, monthly) gave rise to an average daily vitamin D
supplementation dose which was collapsed into four cat-
egories for data analysis purposes (none, 1–2000 IU, 2001–
5000 IU and >5000 IU). Latitude (degrees and minutes)
was obtained from the city and country of residence.
Data analysis
Data were analysed using IBM SPSS Statistics 22.0
(IBM Corporation). Continuous data were summarised
using mean (95 % CI) or median (interquartile range
(IQR)) and categorical data using number (N) and
percentage. Comparisons involving two continuous
variables were undertaken using independent samples
Kruskal-Wallis test as the variables latitude and re-
lapse rate were not normally distributed, with separ-
ate Mann Whitney U tests for post-hoc analyses. For
categorical data Pearson’s Chi Square was used, with
assessment of adjusted standardised residuals to indi-
cate under- or over-representation of groups. For all
inferential tests, two-tailed tests of significance were
used and the criterion for significance was set at .05.
Linear regression was used to predict the Physical
Health and Mental Health composite scores and the
Health Perception and Energy scale scores of the
MSQOL-54 using the three variables of interest: latitude,
deliberate sun exposure, and average daily vitamin D sup-
plementation. First these predictor variables were entered
separately to obtain crude odds ratios (and 95 % CI), and
then together in a multiple linear regression model includ-
ing the variables age, gender, disability, fish consumption,
and physical activity to assess adjusted odds ratios
(95 %CI). Relatively stable factors including gender, age,
disability and fish consumption were included in the re-
gression models as these can impact on the variables of
interest. Physical activity was controlled for as many
people exercise outdoors and it may therefore impact on
sun exposure and vitamin D levels. Multinomial logistic
regression was used to predict disability in a model includ-
ing the variables gender, age, fish consumption and
physical activity. Ordinal logistic regression was used
to predict relapse rate in a model including the vari-
ables disability, gender, age, fish consumption and
physical activity. Testing of assumptions for regres-
sion analysis were performed, including an examin-
ation of multi-collinearity to ensure that continuous
independent variables were not closely correlated (having
a bivariate correlation >0.70). All percentages reported
were adjusted for missing data (due to item non-
completion) on an item by item basis.
Results
Demographics
As previously reported, 2469 people with a self-reported
doctor diagnosis of MS commenced the survey 11. The
sample described here, answering questions regarding lo-
cation of residence, and with a self-reported doctor diag-
nosis of MS consisted of 2466, with varying completion
for other individual items. 1894 (82.3 %) women and 407
(17.7 %) men with MS with a median age of 45 years (IQR
38–53 years), had been diagnosed a median of 6 years
prior (IQR 3–12) and most had relapsing-remitting MS
(1490, 61.6 %). Many worked full time (799, 32.5 %) or
part time (524, 21.3 %) and a significant proportion were
retired due to medical reasons or disability (569, 23.2 %).
Most lived in the United States (807, 32.7 %), Australia
(627, 25.4 %) or the United Kingdom (417, 16.9 %), al-
though 57 countries were represented in total.
Latitude, deliberate sun exposure, and vitamin D
supplementation
Totals of 1592 (64.6 %) and 874 (35.4 %) lived in the
northern and southern hemisphere respectively. Most
people (nearly half ) lived between latitudes 30 and 40
degrees, or for those in the US, between New Orleans
and Columbus, Ohio. The median latitude was 39 degrees
and 83 min (IQR 34.92–48.66). This is approximately the
latitude of Philadelphia in the Northern Hemisphere, or
King Island in the Bass Strait between Australia and
Tasmania, in the Southern Hemisphere. A total of 1504
(66.8 %) reported that they intentionally got sun exposure
to raise their vitamin D level. The majority took vitamin D
supplementation (1794, 81.8 %), mostly between 2000 and
5000 IU on average daily (Table 1).
Latitude was not related to vitamin D supplementation,
or deliberate sun exposure. Vitamin D supplementation
was associated with intentional sun exposure (P < .001)
with those intentionally getting sun exposure more
likely to be taking larger doses (over 2000 IU on
average per day), and those not intentionally getting
sun exposure more likely to be taking lower doses
(2000 IU or less per day).
Quality of life
Additional file 1 displays the results of a regression
model incorporating deliberate sun exposure, latitude and
Table 1 Average daily dose of supplemental vitamin D
(self reported)
Vitamin D dose N Percent
>5000 IU 447 20.4
2001–5000 IU 734 33.5
1–2000 IU 613 28.0
None 399 18.2
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vitamin D supplementation individually with HRQOL out-
comes as well as a regression model incorporating these
variables together with gender, age, disability, physical
activity, and fish consumption (adjusted). The apparent
quality of life associations of deliberate sun exposure appear
to be strongly influenced by the variables being adjusted
for, such that they disappear when the regression model
is adjusted for these variables. In contrast, the apparent
associations of vitamin D supplementation are generally
maintained, although diminished, on adjusting for these
variables, with a dose–response effect and quality of life
differences of clinically significant magnitude. MSQOL-
54 measurements are derived from the SF-36 and it is
generally accepted that a five point increment in this
scale is clinically significant [14, 15].
Disability
Disability was related to latitude (p = .014) with non-
parametric post hoc testing showing a significant differ-
ence in latitude between the mild disability group and
the moderate disability group (p = .009). Median lati-
tudes for these groups were 39.00 (34.83–46.80) for mild
disability, 40.59 (35.30–50.73) for moderate and 41.26
(34.98–51.14) for the high disability group.
Those intentionally getting sun exposure were more
likely to be in the mild disability group and less likely to
be in the moderate or high disability groups compared
to those not intentionally getting sun exposure (p < .001,
Table 2). Vitamin D supplementation was related to dis-
ability also with those taking 2001-5000 IU per day more
likely to be in the mild disability group, and less likely to
be in high disability group while those taking 1–2000 IU
per day were less likely to be in the mild disability group
and more likely to be in the moderate disability group
(p < .001) (Table 3).
After adjusting for gender, age, physical activity, fish
consumption, deliberate sun exposure, and vitamin D
supplementation a logistic regression model revealed
that an increase of latitude by one degree (further away
from the equator) predicted an increased odds of being
in a moderate disability category (OR 1.02 (95 % CI
1.01–1.04), p < .001) or high disability category (OR 1.03
(95 % CI 1.01–1.05), p = .001) compared to being in the
no/mild disability category. None of the other variables
of interest contributed significantly to level of disability
in this model (data not shown).
Relapse rate
Annualised relapse rate was significantly associated with
vitamin D supplementation (p = .001) with significant dif-
ferences between those taking none (mean .92) and all
other groups: those taking 1–2000 IU (mean .63, p < .001);
2001-5000 IU (mean .61, p = .003); and those taking >5000
(mean .62, p < .001). Sensitivity analyses were undertaken
comparing relapse rate according to vitamin D supple-
mentation using non parametric tests which confirmed
the findings of parametric analyses (data not shown).
Differences between other groups were not significant.
Relapse rate was not related to intentional sun exposure
(data not shown).
Ordinal regression incorporating the variables gender,
age, physical activity, fish consumption, deliberate sun ex-
posure, latitude and vitamin D supplementation revealed
that the only variable of interest to significantly predict
relapse rate was latitude, with increase in latitude of 1
degree predicting a 1 % increase in the odds of having
more relapses over the previous 12 months (1.01 (1.00–
1.02), p = .049).
Discussion
Epidemiological data over many years has confirmed the
striking latitude gradient of MS incidence, both world-
wide and within countries. Australia is a good example,
with the incidence of MS varying around seven-fold be-
tween cities in northern versus southern Australia [16].
This has long been postulated to be due to sun expos-
ure, and elegant Australian studies have confirmed that
both recalled time in the sun, particularly winter sun
during childhood, and solar skin damage relate in-
versely to incidence of MS [17]. There are less data
about a relationship between latitude and MS disease
course. However, recent work from the MSBase inter-
national registry examining 32,762 relapses from 9811





Yes N 875a 491b 133b
% 58.4 32.8 8.9
No N 360b 280a 103a
% 48.5 37.7 13.9
aoverrepresented bunderrepresented
Table 3 Vitamin D supplementation and level of disability




>5000 IU N 257 138 52
% 57.5 30.9 11.6
2001–5000 IU N 439a 236 58b
% 59.9 32.2 7.9
1–2000 IU N 293b 243a 74
% 48.0 39.8 12.1
None N 207 140 48
% 52.4 35.4 12.2
aoverrepresented bunderrepresented
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patients across 30 countries from both hemispheres found
a strong seasonal variation in onset of relapses with peaks
in early spring (after a period of decreased sun exposure)
and troughs in autumn in both hemispheres [18]. This
confirmed a prior meta-analysis with similar findings from
the northern hemisphere [19].
There has been a long delay in testing the effects of
vitamin D supplementation on disease course in MS, pre-
sumably due to little commercial incentive to test this non-
patentable naturally occurring agent, however a number of
large international studies are now underway to examine
this issue. Trials to date suggest a benefit, with markedly
reduced conversion of optic neuritis to MS [20] and fewer
lesions when added to existing disease-modifying medica-
tion [21]. While the effect is biologically plausible, it is
possible that higher serum vitamin D levels are just a
marker of increased sun exposure, and it is both the direct
effect, and other as yet unknown indirect effects of sun ex-
posure that mediate beneficial immunomodulatory im-
provements in disease course for PwMS [22, 23].
We sought to shed more light on whether latitude
was associated with disease activity not only disease
incidence, and whether we could detect a signal of a
beneficial effect on disease course and other health
outcomes for PwMS who supplemented with vitamin
D. Our data showed that disability was indeed related
to latitude with increasing disability the further away
from the equator people lived, with a 2–3 % increase
in odds of a higher disability category for each degree
further from the equator. Similarly, there was some
association between lower disability and intentional
sun exposure and increasing dose of vitamin D sup-
plementation. Taking vitamin D supplements was also
associated with around a third lower annualised re-
lapse rate, while increasing latitude was associated
with a small increase in the odds of more relapses.
Intentional sun exposure was not associated with re-
lapse rate in our sample.
There were no associations between quality of life
domains examined and latitude, and those associations
with deliberate sun exposure were not maintained in ad-
justed regression modelling, suggesting a complex rela-
tionship between the variables being adjusted for and sun
exposure. Vitamin D supplementation however did have
clinically significant associations with these quality of life
outcomes, with a dose–response effect suggesting a causal
relationship. Vitamin D supplementation is known to have
quality of life benefits and these associations may reflect
this broader health benefit [24].
Our data suggest a complex relationship between the
variables of interest of latitude, sun exposure and vitamin
D supplementation, and the additional variables controlled
for in our study, namely exercise levels and frequency of
fish consumption. The latter two are both likely to affect
serum vitamin D levels, as well as having associations with
the outcome variables of interest in their own right [25,
26]. Disentangling these relationships statistically in a
large sample can help shed light on the contribution of
these inter-related factors related to health outcomes for
PwMS, but ultimately, these questions are best answered
by randomised controlled trials. For vitamin D supple-
mentation, this should present no particular methodo-
logical problems and is long overdue. For sun exposure,
trial design may be more complex, but the research no
less imperative.
Limitations
Some measures were relatively crude with a simple yes/no
answer in the absence of a validated tool for sun exposure.
We didn’t have an indication of amount of daily sun expos-
ure or life time exposure, but rather whether participants
deliberately exposed themselves to sun for health benefit
and their current location. All measures were self-reported,
and therefore may be subject to recall bias. Vitamin D sup-
plementation was self-reported and not validated with
blood tests. Average daily supplement dose was calculated
and we didn’t take into account differences between those
supplementing with infrequent large doses and those sup-
plementing more frequently with lower doses.
Conclusions
Associations were detected in our large international sam-
ple of PwMS between latitude, deliberate sun exposure
and vitamin D supplementation and health outcomes in-
cluding disability, relapse rate and quality of life. Vitamin
D is likely to have a pivotal role in these associations; its
role in MS health outcomes urgently requires detailed ex-
ploration with well-designed clinical trials.
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